» Articles » PMID: 25006145

Optum Labs: Building a Novel Node in the Learning Health Care System

Overview
Specialty Health Services
Date 2014 Jul 10
PMID 25006145
Citations 198
Authors
Affiliations
Soon will be listed here.
Abstract

Unprecedented change in the US health care system is being driven by the rapid uptake of health information technology and national investments in multi-institution research networks comprising academic centers, health care delivery systems, and other health system components. An example of this changing landscape is Optum Labs, a novel network "node" that is bringing together new partners, data, and analytic techniques to implement research findings in health care practice. Optum Labs was founded in early 2013 by Mayo Clinic and Optum, a commercial data, infrastructure services, and care organization that is part of UnitedHealth Group. Optum Labs now has eleven collaborators and a database of deidentified information on more than 150 million people that is compliant with the Health Insurance Portability and Accountability Act (HIPAA) of 1996. This article describes the early progress of Optum Labs. The combination of the diverse collaborator perspectives with rich data, including deep patient and provider information, is intended to reveal new insights about diseases, treatments, and patients' behavior to guide changes in practice. Practitioners' involvement in agenda setting and translation of findings into practical care innovations accelerates the implementation of research results. Furthermore, feedback loops from the clinic help Optum Labs expand on successes and give quick attention to challenges as they emerge.

Citing Articles

National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling.

Badal K, Staib J, Tice J, Kim M, Eklund M, Wilson L BMJ Open. 2025; 15(2):e089428.

PMID: 39961709 PMC: 11836805. DOI: 10.1136/bmjopen-2024-089428.


Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.

McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M Clin Diabetes. 2025; 43(1):59-70.

PMID: 39829688 PMC: 11739335. DOI: 10.2337/cd24-0007.


Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk.

Neumiller J, Herrin J, Swarna K, Polley E, Galindo R, Umpierrez G Clin J Am Soc Nephrol. 2024; .

PMID: 39729347 PMC: 11835155. DOI: 10.2215/CJN.0000000587.


Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease.

Mehta S, Surapaneni A, Pandit K, Xu Y, Horwitz L, Blecker S J Am Soc Nephrol. 2024; 36(2):290-292.

PMID: 39688374 PMC: 11801770. DOI: 10.1681/ASN.0000000585.


A Normal Forced Vital Capacity Does Not Reliably or Equitably Exclude Restriction.

Moffett A, Balasubramanian A, McCormack M, Aysola J, Halpern S, Weissman G medRxiv. 2024; .

PMID: 39555316 PMC: 11566032. DOI: 10.1101/2024.10.22.24315945.